Skip to main content

Advertisement

SpringerLink
Log in

Migraine prophylaxis: what is new and what we need?

  • Treatment
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

A wide array of options are now available for migraine prophylaxis. Conventional treatments include beta-blockers, anticonvulsants, antidepressants, calcium antagonists and antiserotoninergic drugs. Emerging medications such as ACE inhibitors, sartans and nutritional supplements are gaining favour for migraine prophylaxis. Botulinum toxin type A is a promising therapeutic tool for chronic migraine. Tonabersat is likely to be a step forward for the treatment of migraine with aura. However, much work is needed to identify predictive clinical features of successful responsiveness and to better define the duration of prophylaxis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rasmussen BK (1995) Epidemiology of headache. Cephalalgia 15:45–68

    PubMed  CAS  Google Scholar 

  2. Schoenen J (2006) Neurophysiological features of the migrainous brain. Neurol Sci 27(2):77–81

    Article  Google Scholar 

  3. Olesen J, Burstein R, Ashina M, Tfelt-Hansen P (2009) Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurol 8:679–690

    Article  PubMed  Google Scholar 

  4. Lipton RB, Stewart WF, Diamond S et al (2001) Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 41:646–657

    Article  PubMed  CAS  Google Scholar 

  5. Lipton RB, Bigal ME, Diamond M et al (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68:343–349

    Article  PubMed  CAS  Google Scholar 

  6. Schmitz N, Admiraal-Behloul F, Arkink EB et al (2008) Attack frequency and disease duration as indicators for brain damage in migraine. Headache 48(7):1044–1055

    Article  PubMed  Google Scholar 

  7. Vikelis M, Rapoport AM (2010) Role of antiepileptic drugs as preventive agents for migraine. CNS Drugs 24(1):21–33

    Article  PubMed  CAS  Google Scholar 

  8. Chronicle E, Mulleners W (2004) Anticonvulsant drugs for migraine prophylaxis. Cochrane Database Syst Rev 3: CD003226

  9. Pringsheim T, Davenport WJ, Becker WJ (2010) Prophylaxis of migraine headache. CMAJ 182(7):E269–E276

    Google Scholar 

  10. Wyszynski DF, Nambisan M, Surve T et al (2005) Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 64(6):961–965

    Google Scholar 

  11. Mathew NT, Rapoport A, Saper J et al (2001) Efficacy of gabapentin in migraine prophylaxis. Headache 41:119–128

    Article  PubMed  CAS  Google Scholar 

  12. Galletti F, Cupini LM, Corbelli I et al (2009) Pathophysiological basis of migraine prophylaxis. Prog Neurobiol 89(2):176–192

    Article  PubMed  CAS  Google Scholar 

  13. Linde K, Rossnagel K (2004) Propranolol for migraine prophylaxis. Cochrane Database Syst Rev 2: CD003225

  14. Jackson JL, Shimeall W, Sessums L et al (2010) Tricyclic antidepressants and headaches: systematic review and meta-analysis. BMJ 341: c5222. doi:10.1136/bmj.c5222

  15. Ozyalcin SN, Talu GK, Kiziltan E et al (2005) The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 45(2):144–152

    Article  PubMed  Google Scholar 

  16. Osterman PO (1977) A comparison between placebo, pizotifen and 1-isopropyl-3-hydroxy-5-semicarbazono-6-oxo-2.3.5.6-tetrahydroindol (Divascan) in migraine prophylaxis. Acta Neurol Scand 56(1):17–28

    Article  PubMed  CAS  Google Scholar 

  17. Silberstein SD (1998) Methysergide. Cephalalgia 18(7):421–435

    Article  PubMed  CAS  Google Scholar 

  18. Reveiz-Herault L, Cardona AF, Ospina EG, Carrillo P (2003) Effectiveness of flunarizine in the prophylaxis of migraine: a meta-analytical review of the literature. Rev Neurol 36(10):907–912

    Google Scholar 

  19. Diener HC, Gendolla A, Feuersenger A et al (2009) Telmisartan in migraine prophylaxis: a randomized, placebo-controlled trial. Cephalalgia 29(9):921–927

    Article  PubMed  CAS  Google Scholar 

  20. Tronvik E, Stovner LJ, Bovim G et al (2008) Angiotensin-converting enzyme gene insertion/deletion polymorphism in migraine patients. BMC Neurol 8: 4

    Google Scholar 

  21. Schuh-hofer S, Flach U, Meisel A et al (2007) Efficacy of lisinopril in migraine prophylaxis–an open label study. Eur J Neurol 14(6):701–703

    Article  PubMed  CAS  Google Scholar 

  22. Schoenen J, Jacquy J, Lenaerts M (1998) Effectiveness of high-dose riboflavin in migraine prophylaxis: a randomized controlled trial. Neurology 50:466–470

    PubMed  CAS  Google Scholar 

  23. Sándor P, Di Clemente L, Coppola G et al (2005) Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized, controlled trial. Neurology 64:713–715

    PubMed  Google Scholar 

  24. Peikert A, Wilimzig C, Kohne-Volland R (1996) Prophylaxis of migraine with oral magnesium: results from a prospective, multicentre, placebo-controlled and double blind randomized study. Cephalalgia 16:257–263

    Article  PubMed  CAS  Google Scholar 

  25. Diener HC, Rahlfs VW, Danesch U (2004) The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria. Eur Neurol 51:89–97

    Article  PubMed  CAS  Google Scholar 

  26. Pittler MH, Ernst E (2004) Feverfew for preventing migraine. Cochrane Database Syst Rev (1):CD002286

  27. Shuhendler AJ, Lee S, Siu M et al (2009) Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials. Pharmacotherapy 29(7):784–789

    Article  PubMed  CAS  Google Scholar 

  28. Aurora SK, Dodick DW, Turkel CC et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30(7):793–803

    Article  PubMed  CAS  Google Scholar 

  29. Diener HC, Dodick DW, Aurora SK et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30(7):804–814

    Article  PubMed  CAS  Google Scholar 

  30. Dodick DW, Turkel CC, DeGryse RE et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 50(6):921–936

    Article  PubMed  Google Scholar 

  31. Hauge AW, Asghar MS, Schytz HW et al (2009) Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study. Lancet Neurol 8(8):718–723

    Article  PubMed  CAS  Google Scholar 

  32. Pringsheim T, Davenport WJ, Dodick D (2008) Acute treatment and prevention of menstrually related migraine headache: evidence-based review. Neurology 70(17):1555–1563

    Google Scholar 

Download references

Conflict of interest

The authors declare that there is no actual or potential conflict of interest in relation to this article.

Author information

Authors and Affiliations

  1. Department of Neurological, Motor and Sensorial Sciences, Headache and Pain Unit, IRCCS San Raffaele Pisana, via della Pisana 235, 00163, Rome, Italy

    P. Barbanti, C. Aurilia, G. Egeo & L. Fofi

Authors
  1. P. Barbanti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Aurilia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Egeo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. Fofi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. Barbanti.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barbanti, P., Aurilia, C., Egeo, G. et al. Migraine prophylaxis: what is new and what we need?. Neurol Sci 32 (Suppl 1), 111–115 (2011). https://doi.org/10.1007/s10072-011-0526-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-011-0526-3

Keywords

Search

Navigation